You are here

Press Release Archive

- New survey on Atlanta Attitudes Toward Aging To Be Released Thursday, July 11




On July 11, 2013 Pfizer and Generations United will release results of an inter-generational survey of Atlanta respondents attitudes towards aging. The “2013 Get Old Survey” reveals that Atlanta-area residents of all ages are concerned about their ability to get old the way they want, and feel their communities are not prepared to support an aging population.


- Eliquis® (apixaban) Demonstrated Comparable Efficacy And Significantly Lower Rates Of Major Bleeding In Patients Compared To Current Standard Of Care For The Treatment Of Acute Venous Thromboembolism

PRINCETON, NJ and NEW YORK, June 30 – Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the six month Phase 3 AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

- Pfizer Declares 24-Cent Third-Quarter 2013 Dividend

NEW YORK, N.Y., June 27 – The board of directors of Pfizer Inc. today declared a 24-cent third-quarter 2013 dividend on the company’s common stock, payable September 4, 2013, to shareholders of record at the close of business on August 2, 2013.  The third-quarter 2013 cash dividend will be the 299th consecutive quarterly dividend paid by Pfizer.


- Pfizer Announces Final Results of Zoetis Exchange Offer

NEW YORK, N.Y. June 27 – Pfizer Inc. (NYSE: PFE) today announced the final results of its offer to its shareholders to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis Inc. (NYSE: ZTS)  common stock owned by Pfizer.


- Advil® Is The Official Pain Reliever Of Tough Mudder® Bringing #ReliefinAction To “Probably The Toughest Event On The Planet”

Madison, N.J., June 26 Pfizer Inc. (NYSE: PFE) announces today that Advil® is the Official Pain Reliever of Tough Mudder® as part of the Advil® Relief in Action campaign that celebrates volunteers who don’t let pain get in the way of providing relief to others.


- Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts

NEW YORK, N.Y., June 25 -- Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 30, 2013.  The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2013 Performance Report, to be issued that morning.


- Pfizer Announces Preliminary Results of Zoetis Exchange Offer and Adjusts 2013 Financial Guidance(1) Solely to Reflect Impact of Exchange Offer

Pfizer Inc. (NYSE: PFE) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis Inc. 

- Pfizer Announces FDA Acceptance For Review Of Application To Expand Labeling For XELJANZ® (tofacitinib citrate) For Adults With Moderately To Severely Active Rheumatoid Arthritis To Include Inhibition Of Progression Of Structural Damage

NEW YORK, N.Y., June 21 - Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA)for the XELJANZ® (tofacitinib citrate) rheumatoid arthritis (RA) indication seeking expansion of the label to include inhibition of progression of structural damage.  The FDA will review the sNDA and is expected to provide a decision by February 2014, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date for the sNDA.


- Pfizer Announces Final Exchange Ratio Of 0.9898 For Zoetis Exchange Offer And Automatic Extension Of Offer To Midnight On Friday, June 21, 2013

NEW YORK, N.Y., June 19 – Pfizer Inc. (NYSE: PFE) today announced the final exchange ratio in connection with its previously announced offer to its shareholders to exchange some or all of their shares of Pfizer common stock for shares of Zoetis Inc. (NYSE: ZTS) common stock held by Pfizer.


- Pfizer Obtains $2.15 Billion Settlement From Teva And Sun For Infringement Of Protonix® Patent

NEW YORK, N.Y., June 12 – Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk” launches of generic Protonix® in the United States.  The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine.  Pfizer and Takeda will divide the proceeds of the settlement with Pfizer receiving 64 percent.


- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Goldman Sachs 34th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 8:40 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at and click on the “Goldman Sachs 34th Annual Global Healthcare Conference”

- Americans Believe Their Communities Are Ill-Prepared For Aging Population, New Survey Reveals; Survey Shows A Fear Of Getting Old Due To Health And Financial Concerns

(BUSINESS WIRE)--Nearly nine out of ten people who live in the U.S. believe they will live a long life, yet 40 percent believe being old is something to fear due to potential health and financial concerns, according to the second annual Get Old survey. Despite rising rates of chronic disease estimated to affect nearly half (49%) the U.S. population by 2025, survey respondents expressed a surprising degree of comfort with the current state of theirmore...

- Pfizer Prices $4.0 Billion Debt Offering

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering
consisting of five tranches of notes:

$750,000,000 aggregate principal amount of 0.900% notes due 2017

$1,000,000,000 aggregate principal amount of 1.500% notes due 2018

$500,000,000 aggregate principal amount of floating rate notes due 2018

$1,000,000,000 aggregate principal amount of 3.000% notes due 2023more...

- Pfizer Announces Plan for Split-Off of Zoetis

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to split off its
remaining interest in Zoetis Inc. (NYSE: ZTS), through an exchange
offer. Zoetis, formerly Pfizer’s animal health business, completed its
initial public offering (IPO) in February 2013. In the exchange offer,
Pfizer shareholders can exchange all, some or none of their shares of
Pfizer common stock for shares of Zoetis common stock owned by Pfizer.
The exchange offer ismore...


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.